IMTX Latest Headlines

Clear Street Reaffirms Their Buy Rating on Immatics (IMTX)

at www.tipranks.com (Thu, 11-Dec 1:15 PM)

Immatics Reveals Promising Results from IMA203CD8 Phase 1a Trial

at www.tipranks.com (Thu, 11-Dec 7:29 AM)

Immatics Completes $116.5 Million Share Offering to Boost R&D

at www.tipranks.com (Mon, 8-Dec 4:54 PM)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immatics (IMTX), Incyte (INCY) and Cogent Biosciences (COGT)

at www.tipranks.com (Mon, 8-Dec 5:50 AM)

Immatics Launches $125 Million Underwritten Offering—What Could This Mean for Its Clinical Pipeline?

Market Chameleon (Fri, 5-Dec 9:01 AM)

Immatics Advances PRAME Franchise With Multiple Clinical Milestones and Expands Cash Runway to Late 2027

Market Chameleon (Mon, 17-Nov 7:09 AM)

Immatics Unveils Promising Clinical Results for Next-Gen TCR Bispecifics—30% Confirmed Response Rate for IMA402 in Advanced Solid Tumors

Market Chameleon (Wed, 12-Nov 7:08 AM)